Administration of the quadrivalent HPV vaccine was not associated with excess risk for adverse outcomes.
Immunization with quadrivalent human papillomavirus (HPV) vaccine (Gardasil) is recommended for girls and young women (age range, 9 to 26), a period of childbearing potential. Now, two studies provide new information about outcomes following HPV vaccination during pregnancy.
In the first study, researchers assessed data from a pregnancy registry of women who inadvertently received the HPV vaccine while pregnant. The registry identified 863 women who were immunized within 30 days of their last menstrual period. Of 517 pregnancies with known outcomes, 451 resulted in live births (454 neonates). Of 454 neonates, 439 (97%) were normal, and 10 had major birth defects (prevalence, 2.2 per 100 liveborn neonates) without particular patterns of organ…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)